Defining total-body AIDS-virus burden with implications for curative strategies

Jacob D. Estes, Cissy Kityo, Francis Ssali, Louise Swainson, Krystelle Nganou Makamdop, Gregory Q. Del Prete, Steven G. Deeks, Paul A Luciw, Jeffrey G. Chipman, Gregory J. Beilman, Torfi Hoskuldsson, Alexander Khoruts, Jodi Anderson, Claire Deleage, Jacob Jasurda, Thomas E. Schmidt, Michael Hafertepe, Samuel P. Callisto, Hope Pearson, Thomas ReimannJared Schuster, Jordan Schoephoerster, Peter Southern, Katherine Perkey, Liang Shang, Stephen W. Wietgrefe, Courtney V. Fletcher, Jeffrey D. Lifson, Daniel C. Douek, Joseph M. McCune, Ashley T. Haase, Timothy W. Schacker

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

In the quest for a functional cure or the eradication of HIV infection, it is necessary to know the sizes of the reservoirs from which infection rebounds after treatment interruption. Thus, we quantified SIV and HIV tissue burdens in tissues of infected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans. Before antiretroviral therapy (ART), LTs contained >98% of the SIV RNA + and DNA + cells. With ART, the numbers of virus (v) RNA+ cells substantially decreased but remained detectable, and their persistence was associated with relatively lower drug concentrations in LT than in peripheral blood. Prolonged ART also decreased the levels of SIV- and HIV-DNA + cells, but the estimated size of the residual tissue burden of 10 8 vDNA + cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption. The large sizes of these tissue reservoirs underscore challenges in developing 'HIV cure' strategies targeting multiple sources of virus production.

Original languageEnglish (US)
Pages (from-to)1271-1276
Number of pages6
JournalNature Medicine
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Viruses
Lymphoid Tissue
HIV
Tissue
Proviruses
RNA Viruses
DNA
Therapeutics
Cell Size
Primates
HIV Infections
RNA
Biopsy
Infection
Pharmaceutical Preparations
Blood

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Estes, J. D., Kityo, C., Ssali, F., Swainson, L., Makamdop, K. N., Del Prete, G. Q., ... Schacker, T. W. (2017). Defining total-body AIDS-virus burden with implications for curative strategies. Nature Medicine, 23(11), 1271-1276. https://doi.org/10.1038/nm.4411

Defining total-body AIDS-virus burden with implications for curative strategies. / Estes, Jacob D.; Kityo, Cissy; Ssali, Francis; Swainson, Louise; Makamdop, Krystelle Nganou; Del Prete, Gregory Q.; Deeks, Steven G.; Luciw, Paul A; Chipman, Jeffrey G.; Beilman, Gregory J.; Hoskuldsson, Torfi; Khoruts, Alexander; Anderson, Jodi; Deleage, Claire; Jasurda, Jacob; Schmidt, Thomas E.; Hafertepe, Michael; Callisto, Samuel P.; Pearson, Hope; Reimann, Thomas; Schuster, Jared; Schoephoerster, Jordan; Southern, Peter; Perkey, Katherine; Shang, Liang; Wietgrefe, Stephen W.; Fletcher, Courtney V.; Lifson, Jeffrey D.; Douek, Daniel C.; McCune, Joseph M.; Haase, Ashley T.; Schacker, Timothy W.

In: Nature Medicine, Vol. 23, No. 11, 01.11.2017, p. 1271-1276.

Research output: Contribution to journalArticle

Estes, JD, Kityo, C, Ssali, F, Swainson, L, Makamdop, KN, Del Prete, GQ, Deeks, SG, Luciw, PA, Chipman, JG, Beilman, GJ, Hoskuldsson, T, Khoruts, A, Anderson, J, Deleage, C, Jasurda, J, Schmidt, TE, Hafertepe, M, Callisto, SP, Pearson, H, Reimann, T, Schuster, J, Schoephoerster, J, Southern, P, Perkey, K, Shang, L, Wietgrefe, SW, Fletcher, CV, Lifson, JD, Douek, DC, McCune, JM, Haase, AT & Schacker, TW 2017, 'Defining total-body AIDS-virus burden with implications for curative strategies', Nature Medicine, vol. 23, no. 11, pp. 1271-1276. https://doi.org/10.1038/nm.4411
Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nature Medicine. 2017 Nov 1;23(11):1271-1276. https://doi.org/10.1038/nm.4411
Estes, Jacob D. ; Kityo, Cissy ; Ssali, Francis ; Swainson, Louise ; Makamdop, Krystelle Nganou ; Del Prete, Gregory Q. ; Deeks, Steven G. ; Luciw, Paul A ; Chipman, Jeffrey G. ; Beilman, Gregory J. ; Hoskuldsson, Torfi ; Khoruts, Alexander ; Anderson, Jodi ; Deleage, Claire ; Jasurda, Jacob ; Schmidt, Thomas E. ; Hafertepe, Michael ; Callisto, Samuel P. ; Pearson, Hope ; Reimann, Thomas ; Schuster, Jared ; Schoephoerster, Jordan ; Southern, Peter ; Perkey, Katherine ; Shang, Liang ; Wietgrefe, Stephen W. ; Fletcher, Courtney V. ; Lifson, Jeffrey D. ; Douek, Daniel C. ; McCune, Joseph M. ; Haase, Ashley T. ; Schacker, Timothy W. / Defining total-body AIDS-virus burden with implications for curative strategies. In: Nature Medicine. 2017 ; Vol. 23, No. 11. pp. 1271-1276.
@article{edcea6ace1a14d0b8526327769627f22,
title = "Defining total-body AIDS-virus burden with implications for curative strategies",
abstract = "In the quest for a functional cure or the eradication of HIV infection, it is necessary to know the sizes of the reservoirs from which infection rebounds after treatment interruption. Thus, we quantified SIV and HIV tissue burdens in tissues of infected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans. Before antiretroviral therapy (ART), LTs contained >98{\%} of the SIV RNA + and DNA + cells. With ART, the numbers of virus (v) RNA+ cells substantially decreased but remained detectable, and their persistence was associated with relatively lower drug concentrations in LT than in peripheral blood. Prolonged ART also decreased the levels of SIV- and HIV-DNA + cells, but the estimated size of the residual tissue burden of 10 8 vDNA + cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption. The large sizes of these tissue reservoirs underscore challenges in developing 'HIV cure' strategies targeting multiple sources of virus production.",
author = "Estes, {Jacob D.} and Cissy Kityo and Francis Ssali and Louise Swainson and Makamdop, {Krystelle Nganou} and {Del Prete}, {Gregory Q.} and Deeks, {Steven G.} and Luciw, {Paul A} and Chipman, {Jeffrey G.} and Beilman, {Gregory J.} and Torfi Hoskuldsson and Alexander Khoruts and Jodi Anderson and Claire Deleage and Jacob Jasurda and Schmidt, {Thomas E.} and Michael Hafertepe and Callisto, {Samuel P.} and Hope Pearson and Thomas Reimann and Jared Schuster and Jordan Schoephoerster and Peter Southern and Katherine Perkey and Liang Shang and Wietgrefe, {Stephen W.} and Fletcher, {Courtney V.} and Lifson, {Jeffrey D.} and Douek, {Daniel C.} and McCune, {Joseph M.} and Haase, {Ashley T.} and Schacker, {Timothy W.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/nm.4411",
language = "English (US)",
volume = "23",
pages = "1271--1276",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Defining total-body AIDS-virus burden with implications for curative strategies

AU - Estes, Jacob D.

AU - Kityo, Cissy

AU - Ssali, Francis

AU - Swainson, Louise

AU - Makamdop, Krystelle Nganou

AU - Del Prete, Gregory Q.

AU - Deeks, Steven G.

AU - Luciw, Paul A

AU - Chipman, Jeffrey G.

AU - Beilman, Gregory J.

AU - Hoskuldsson, Torfi

AU - Khoruts, Alexander

AU - Anderson, Jodi

AU - Deleage, Claire

AU - Jasurda, Jacob

AU - Schmidt, Thomas E.

AU - Hafertepe, Michael

AU - Callisto, Samuel P.

AU - Pearson, Hope

AU - Reimann, Thomas

AU - Schuster, Jared

AU - Schoephoerster, Jordan

AU - Southern, Peter

AU - Perkey, Katherine

AU - Shang, Liang

AU - Wietgrefe, Stephen W.

AU - Fletcher, Courtney V.

AU - Lifson, Jeffrey D.

AU - Douek, Daniel C.

AU - McCune, Joseph M.

AU - Haase, Ashley T.

AU - Schacker, Timothy W.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - In the quest for a functional cure or the eradication of HIV infection, it is necessary to know the sizes of the reservoirs from which infection rebounds after treatment interruption. Thus, we quantified SIV and HIV tissue burdens in tissues of infected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans. Before antiretroviral therapy (ART), LTs contained >98% of the SIV RNA + and DNA + cells. With ART, the numbers of virus (v) RNA+ cells substantially decreased but remained detectable, and their persistence was associated with relatively lower drug concentrations in LT than in peripheral blood. Prolonged ART also decreased the levels of SIV- and HIV-DNA + cells, but the estimated size of the residual tissue burden of 10 8 vDNA + cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption. The large sizes of these tissue reservoirs underscore challenges in developing 'HIV cure' strategies targeting multiple sources of virus production.

AB - In the quest for a functional cure or the eradication of HIV infection, it is necessary to know the sizes of the reservoirs from which infection rebounds after treatment interruption. Thus, we quantified SIV and HIV tissue burdens in tissues of infected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans. Before antiretroviral therapy (ART), LTs contained >98% of the SIV RNA + and DNA + cells. With ART, the numbers of virus (v) RNA+ cells substantially decreased but remained detectable, and their persistence was associated with relatively lower drug concentrations in LT than in peripheral blood. Prolonged ART also decreased the levels of SIV- and HIV-DNA + cells, but the estimated size of the residual tissue burden of 10 8 vDNA + cells potentially containing replication-competent proviruses, along with evidence of continuing virus production in LT despite ART, indicated two important sources for rebound following treatment interruption. The large sizes of these tissue reservoirs underscore challenges in developing 'HIV cure' strategies targeting multiple sources of virus production.

UR - http://www.scopus.com/inward/record.url?scp=85033233189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033233189&partnerID=8YFLogxK

U2 - 10.1038/nm.4411

DO - 10.1038/nm.4411

M3 - Article

C2 - 28967921

AN - SCOPUS:85033233189

VL - 23

SP - 1271

EP - 1276

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -